QUANTIFICATION OF CRYSTALLINITY IN BLENDS OF LYOPHILIZED AND CRYSTALLINE MK-0591 USING X-RAY-POWDER DIFFRACTION

被引：34

作者：

CLAS, SD

FAIZER, R

OCONNOR, RE

VADAS, EB

机构：

[1] Merck Frosst Centre for Therapeutic Research, Pointe Claire-Dorval H9R 4P8

来源：

INTERNATIONAL JOURNAL OF PHARMACEUTICS | 1995年 / 121卷 / 01期

关键词：

L-686,708; MK-0591; LEUKOTRIENE BIOSYNTHESIS INHIBITOR; X-RAY POWDER DIFFRACTION; CRYSTALLINITY; QUANTITATIVE DETERMINATION;

D O I：

10.1016/0378-5173(95)00008-7

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

X-ray powder diffraction was used to determine the percent crystallinity in blends of crystalline and X-ray amorphous MK-0591, a potent indirect leukotriene biosynthesis inhibitor. A linear calibration curve was obtained. Preliminary studies using powder blends of MK-0591 with pregelatinized starch, microcrystalline cellulose, and magnesium stearate demonstrated the feasibility of using this method to determine (or quantify) the percent crystallinity of MK-0591 in tablet formulations.

引用

页码：73 / 79

页数：7

共 17 条

[1]

BELLEY ML, 1991, Patent No. 419049

[2] POLYMORPHISM OF 1,2-DIHYDRO-6-NEOPENTYL-2-OXONICOTINIC ACID - CHARACTERIZATION, INTERCONVERSION, AND QUANTITATION [J].

CHAO, RS ;

VAIL, KC .

PHARMACEUTICAL RESEARCH, 1987, 4 (05) :429-432

[3]

CLAS SD, 1995, UNPUB INT J PHARM

[4]

DOWN B, 1993, Patent No. 5254567

[5]

EVANS JF, 1991, MOL PHARMACOL, V40, P22

[6]

IMAIZUMI H, 1980, CHEM PHARM BULL, V28, P2565

[7]

JENKINS R, INTRO XRAY POWDER DI, P26

[8]

KITAMURA S, 1989, INT J PHARM, V56, P125

[9]

KLUG HP, 1954, XRAY DIFFRACTION PRO

[10] THE DOPING METHOD IN QUANTITATIVE X-RAY-DIFFRACTION PHASE-ANALYSIS - ADDENDUM [J].

POPOVIC, S ;

GRZETAPLENKOVIC, B ;

BALICZUNIC, T .

JOURNAL OF APPLIED CRYSTALLOGRAPHY, 1983, 16 (OCT) :505-507

← 1 2 →